ProKidney
PROK

$2.45

0.83%

Market Cap: 283M

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

Employees: 163

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

3.75% less ownership

Funds ownership: 43.76% [Q4 2023] → 40.01% (-3.75%) [Q1 2024]

10% less funds holding

Funds holding: 61 [Q4 2023] → 55 (-6) [Q1 2024]

16% less capital invested

Capital invested by funds: $52.3M [Q4 2023] → $44.1M (-$8.16M) [Q1 2024]

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 24

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $10K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$3

22%

upside

Avg. target

$4.33

77%

upside

High target

$6

145%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

Jefferies Kelly Shi	145%upside $6	Buy Maintained	10 Jun 2024
B of A Securities Jason Gerberry	63%upside $4	Neutral Maintained	29 May 2024
Morgan Stanley Judah Frommer	22%upside $3	Equal-Weight Assumed	7 Mar 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Play Likely Earnings Beat With 3 Top-Ranked Stocks

Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.

Play Likely Earnings Beat With 3 Top-Ranked Stocks

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering.

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company.

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates. Management will host a live webcast today at 8:00 a.m. ET to discuss the data.

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

ProKidney to Participate in the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY.

ProKidney to Participate in the Jefferies Global Healthcare Conference

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population. To register, click here .

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended March 31, 2024.

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

ProKidney to Participate in Jefferies Biotech on the Bay Summit

WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024.

ProKidney to Participate in Jefferies Biotech on the Bay Summit

See News Rankings